sumatriptan succinate / Generic mfg. - LARVOL DELTA

RhIII-catalyzed C-H heteroarylation and C-N cleavage: direct access to C2-heteroarylated (NH)-indoles. (PubMed, Org Biomol Chem) - "This catalytic methodology tolerated a diverse range of heterocyclic boronates and indoles well. Successful late-stage modification of the antimigraine drug sumatriptan further highlights its potential utility in the preparation of indole-based pharmaceutical molecules."

Journal • CNS Disorders • Migraine • Pain

Inhaled 5-HT1B /1D Receptor Antagonist Attenuates Sumatriptan-Induced Sensitization of Capsaicin-Sensitive Lung Vagal Afferents: Implications for Preventing Sumatriptan-Associated Adverse Chest Symptoms. (PubMed, Compr Physiol) - "Inhalation of a 5-HT1B/1D receptor antagonist effectively prevented sumatriptan-induced sensitization of CSLV afferents without diminishing sumatriptan's antimigraine efficacy. Our findings suggest that inhaled 5-HT1B/1D antagonists may offer a promising strategy to prevent or treat sumatriptan-induced adverse chest symptoms."

Journal • Anesthesia • CNS Disorders • Hypotension • Migraine • Pain • Pulmonary Disease

Ischemic Stroke in a 28-Year-Old Young Adult Associated With Chronic Triptan and Non-Steroidal Anti-Inflammatory Drug (NSAID) Use. (PubMed, Cureus) - "Her medical history was notable for chronic migraine treated with daily sumatriptan use over three years and intermittent administration of diclofenac (Fastenal), a non-selective NSAID, used as needed for pain control...It also highlights the potential contributory role of chronic vasoconstrictive migraine therapies in conjunction with non-steroidal anti-inflammatory drug (NSAID) use and minor metabolic abnormalities in precipitating ischemic stroke in young adults. Increased clinical vigilance is warranted when evaluating young migraine patients presenting with acute focal neurological deficits."

Journal • Cardiovascular • CNS Disorders • Dyslipidemia • Endocrine Disorders • Ischemic stroke • Metabolic Disorders • Migraine • Pain

MAMBO-II: Randomized Cross-Over Experimental Trial of Treatment with Sumatriptan vs. Rimegepant During Nitroglycerin (NTG)-Induced Headache in Patients with Episodic Migraine for the Determination of Molecular and Clinical Biomarkers (MAMBO II Study). (clinicaltrialsregister.eu) - P4 | N=24 | Recruiting | Sponsor: Fundacio Hospital Universitari Vall DHebron Institut De Recerca | Not yet recruiting ➔ Recruiting

Biomarker • Enrollment open • CNS Disorders • Migraine • Pain

Network Meta-analysis of Atzumi (STS101) Dihydroergotamine Nasal Powder Versus Modern Oral and Intranasal Agents for the Acute Treatment of Migraine (AAN 2026) - "In contrast, zavegepant 10 mg IN, ubrogepant 50 mg PO, and rimegepant 75 mg ODT achieved PF RRs of 1.49, 1.52, and 1.46, respectively, while sumatriptan 100 mg PO remained highest (1.88 [1.64–2.15]). Atzumi (STS101) showed sustained efficacy beyond 3 hours with excellent tolerability, offering a safe non-oral option for acute migraine; overall study quality was high with low ROB 2.0."

Retrospective data • CNS Disorders • Migraine • Pain

New-onset TAC Following a Trip to New Mexico: An Initial Presentation of CLL with CNS Involvement (AAN 2026) - "TAC was considered, however both indomethacin and sumatriptan were ineffective. Notably, serial courses of prednisone provided excellent transient relief...He was transferred to Oncology for staging and initiation of Rituximab... Secondary causes of TAC should be considered in patients with red flag features or exam findings. Atypical symptoms in this patient's case included travel history, rapid escalation of symptoms, exquisite symptomatic response to steroids, and poor response to standard therapies. Atypical signs included papilledema and persistent lymphadenopathy."

Chronic Lymphocytic Leukemia • Cognitive Disorders • Hematological Malignancies • Infectious Disease • Leukemia

Pharmacokinetics and Safety of Lu AG09222, an Anti-PACAP Monoclonal Antibody in Development for Migraine Prevention (AAN 2026) - "Background: Lu AG09222 is a humanised monoclonal antibody targeting pituitary adenylate cyclase-activating polypeptide (PACAP) that is in development for migraine prevention.Design/ Data were included from a (1) first-in-human single ascending dose trial in healthy participants, including a cohort with co-administered sumatriptan (Lu AG09222 n=68; placebo n=28); (2) single-dose trial in healthy Caucasian, Chinese, and Japanese participants (Lu AG09222 n=40; placebo n=12); and (3) multiple-dose trial in participants with symptomatic allergic rhinitis (Lu AG09222 n=20; placebo n=10). Lu AG09222 exhibited a consistent PK profile across dosing regimens, route of administration and race/ethnicity. Across these trials, no safety concerns were identified, and Lu AG09222 was generally well-tolerated."

Clinical • First-in-human • PK/PD data • Allergic Rhinitis • CNS Disorders • Immunology • Inflammation • Migraine • Pain • ADCYAP1

A Case of Acute Migrainous Infarction: A Rare Complication of Migraine with Aura (AAN 2026) - "After this initial examination, she received sumatriptan... MI is a rare disorder that predominantly affects young women with MWA and typically occurs in the posterior circulation. At presentation, it can be difficult to differentiate migraine aura from infarct, and it is imperative to keep this potential diagnosis in mind when determining indication for thrombolytic administration and contraindications to triptans."

Clinical • Cardiovascular • CNS Disorders • Ischemic stroke • Migraine • Pain • Rare Diseases

Migraine to Mesenteric Mishap: A Case Report of Ischemic Colitis Due to Sumatriptan. (PubMed, Cureus) - "The patient had been using nonsteroidal anti-inflammatory drugs for many years, then initiated high doses of the 5-hydroxytryptamine receptor agonist sumatriptan prior to her first episode of IC, suggesting that sumatriptan was the primary etiology. This case represents the patient's third episode of IC, highlighting the importance of thorough medication review in identifying potential etiologies."

Journal • Back Pain • Cardiovascular • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Immunology • Migraine • Musculoskeletal Pain • Pain

Management of migraine in children and adolescents: A systematic review of guidelines and practice recommendations. (PubMed, Cephalalgia) - "As regards management, paracetamol and ibuprofen were considered first line in the acute management of migraine, with sumatriptan and zolmitriptan nasal sprays rated as second line. Various non-pharmacological measures gained attention in all guidelines. Notably, CGRP antagonists and non-invasive neuromodulation techniques were identified as major gaps.ConclusionThe current systematic review highlights areas of agreement and disagreement between existing guidelines on the management of childhood and adolescent migraine and emphasizes the current gaps and opportunities, thus offering a solid foundation for future studies and guidelines."

Journal • Review • CNS Disorders • Migraine • Pain • Pediatrics

Multiple Sclerosis With Migraine and Pyoderma Gangrenosum Treated With Ofatumumab and Erenumab. (PubMed, Cureus) - "She experienced persistent migraines despite valproic acid and sumatriptan use. After the administration of intravenous methylprednisolone (IVMP), ofatumumab treatment was introduced; erenumab was later initiated to manage migraines...The combination therapy demonstrated effectiveness without exacerbating the patient's underlying dermatological condition. This case suggests that combining ofatumumab and erenumab is a viable therapeutic option for patients with MS and comorbid migraine and pyoderma gangrenosum, offering effective disease control with an acceptable safety profile."

Journal • CNS Disorders • Migraine • Multiple Sclerosis • Pain • Pyoderma Gangrenosum

Spatial metabolomics combined with MALDI-MSI unveils gut-brain axis mechanisms of angelica dahurica radix in migraine rats. (PubMed, Phytomedicine) - "Baizhi alleviates migraine through multi-target regulation of the gut-brain axis, including intestinal barrier repair, gut microbiota remodeling, and cerebral metabolic restoration. Notably, this study on Baizhi represents the first integration of spatial metabolomics (MALDI-MSI) with gut microbiome and systemic metabolomics to elucidate migraine mechanisms, providing a novel multi-omics strategy for understanding the holistic therapeutic effects of traditional Chinese medicine. These findings provide a mechanistic basis for its clinical application in migraine treatment."

Journal • Preclinical • CNS Disorders • Metabolic Disorders • Migraine • Pain • Solid Tumor • OCLN • TJP1 • TNFA

Treating the Pain After the Cure: Therapeutic Approaches for Post-ECT Headache-A Systematic Review. (PubMed, J ECT) - "Treatments evaluated included sumatriptan, nonsteroidal anti-inflammatory drugs (NSAIDs), paracetamol, propranolol, topiramate, valproic acid, mirtazapine, dihydroergotamine, topical salicylates, cryotherapy, and percutaneous electrical nerve stimulation. However, clinical phenotyping and a stepwise therapeutic approach may improve symptom control. This review provides a comprehensive summary of current options and offers guidance for individualized management of post-ECT headache."

Journal • CNS Disorders • Migraine • Musculoskeletal Pain • Pain

Investigating organic cation transporter 1 in drug interactions: New findings from in vitro and in vivo cynomolgus monkey studies. (PubMed, Drug Metab Dispos) - "Transport assays in transfected human embryonic kidney 293 cells showed that sumatriptan, fenoterol, metformin, quinidine, and 1-methyl-4-phenylpyridinium were transported by cOCT1 at rates comparable to hOCT1 (less than 2-fold difference)...Consistent with our in vitro findings, coadministration of OCT1 inhibitors (axitinib, nintedanib, and erlotinib) significantly increased the systemic exposure of sumatriptan in monkeys. These findings offer valuable insights into the role of OCT1 in drug-drug interactions and highlight the potential of cynomolgus monkeys as a useful and potentially translational model for OCT1-mediated disposition and interactions."

Journal • Preclinical • SLC22A1

Refractory chronic cluster headache: A new therapeutic option (EHF-EHC 2025) - "Acute therapy with oral zolmitriptan 5 mg, subcutaneous sumatriptan 6 mg, and oxygen were used, with moderate effect. Preventive treatment included prednisolone and occipital nerve block during exacerbations, and verapamil, both as monotherapy and in combination with topiramate and lithium in various regimens... Treating refractory chronic cluster headache is challenging, as it is highly disabling for the patient. Although other therapies targeting CGRP have not shown clear benefit in clinical trials, especially in chronic forms, atogepant may offer a promising alternative."

Anorexia • Cardiovascular • Chronic Cluster Headache • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Hypertension • Migraine • Pain

Pharmacokinetics and safety of Lu AG09222, an antiPACAP monoclonal antibody in development for migraine prevention (EHF-EHC 2025) - " Data were included from a (1) first-inhuman single ascending dose trial in healthy participants, including a cohort with co-administered sumatriptan (Lu AG09222 n=68; placebo n=28); (2) single-dose trial in healthy Caucasian, Chinese, and Japanese participants (Lu AG09222 n=40; placebo n=12); and (3) multiple-dose trial in participants with symptomatic allergic rhinitis (Lu AG09222 n=20; placebo n=10). Lu AG09222 exhibited a consistent PK profile across dosing regimens, route of administration and race/ethnicity. Across these trials, no safety concerns were identified, and Lu AG09222 was generally well-tolerated."

Clinical • PK/PD data • Allergic Rhinitis • CNS Disorders • Immunology • Inflammation • Migraine • Pain • ADCYAP1

Comparative analysis of efficacy between sumatriptan and naratriptan in the abortive treatment of migraine (EHF-EHC 2025) - "Sumatriptan and Naratriptan are both effective in the abortive treatment of oral migraine; however, they possess distinct characteristics. Therefore, factors such as time to pain relief, duration of effect, recurrence rate of attacks, and cardiovascular adverse effects should be considered. Thus, the choice between the two medications should be made based on the patient's profile and clinical needs for attack control, considering both efficacy and safety profile."

Clinical • Cardiovascular • CNS Disorders • Migraine • Pain

Clinical-genotype machine prescription for migraine – A HUNT study (EHF-EHC 2025) - " In total, 475 participants tried a preventive (amitriptyline, beta-blocker, candesartan or topiramate) and 565 a triptan (371 sumatriptan) during the project period. We developed models that predicted treatment responses to amitriptyline, beta-blockers, candesartan and topiramate with modest accuracy. Incorporating genetic data did not enhance performance, although the limited sample size prevents firm conclusions. Figure 1."

Clinical • CNS Disorders • Migraine • Pain

Behavioural characterisation of a codeine-induced medication overuse headache model in mice: Focus on pain-related behaviour and cognitive impairment (EHF-EHC 2025) - "After the 12-day drug-free period (day 21), we assessed the development of periorbital allodynia following application of a low nitroglycerin dose. Codeine induced cutaneous allodynia and cognitive impairment in mice, with effects comparable to those of sumatriptan. These results support the idea of codeine-induced model of MOH as a promising preclinical tool for studying MOH and its consequences. Fig."

Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Migraine • Pain

Recurrent severe headache with a background of functional vomiting and normal brain MRI, in paediatric reversible cerebral vasoconstriction syndrome (RCVS) (EHF-EHC 2025) - "Sumatriptan had made his headaches worse... After the diagnosis of RCVS, he was started on oral Nimodipine and his headaches events reduce in frequency and severity to once a day... RCVS is a rare condition normally seen in middle age. The pathogenesis is unknown and recurrence is uncommon. Severe cases can lead to stroke due to vasoconstriction."

Cardiovascular • Chronic Kidney Disease • CNS Disorders • Cognitive Disorders • Migraine • Pain • Pediatrics

Paracetamol (Acetaminophen) and caffeine combination in headache management (EHF-EHC 2025) - "Two other TTH clinical trials have shown that the efficacy and safety of combination was comparable to Naproxen 550 mg and Ibuprofen 400 mg. One randomized, cross-over trial has shown a comparable efficacy/safety profile of the combination vs sumatriptan 50 mg in treatment of migraine attack. Caffeine accelerates and prolongs the analgesic effect of paracetamol over time with a significant improvement of pain relief in patients with primary headaches without added safety issues."

CNS Disorders • Migraine • Pain • ADORA2A

Arc-mediated synaptic plasticity regulates cognitive function in a migraine mouse model (EHF-EHC 2025) - " C57BL/6 mice were randomly divided into four groups: the IS group (migraine model induced by inflammatory soup, IS), IS+M group (IS model + memantine treatment), IS+S group (IS model + sumatriptan treatment), and a control group (PBS with no IS stimulation). Cognitive dysfunction in the migraine model was associated with impaired synaptic plasticity, as indicated by reduced Arc expression. Memantine treatment alleviated cognitive deficits and restored synaptic function, suggesting that Arcmediated synaptic plasticity may play a critical role in migraine-related cognitive impairment and could be a potential therapeutic target. Fig."

Preclinical • ADHD (Impulsive Aggression) • Alzheimer's Disease • Attention Deficit Hyperactivity Disorder • CNS Disorders • Cognitive Disorders • Migraine • Pain

Does heterogeneity in patient population, study design, and endpoint definitions affect indirect comparisons of acute migraine treatments? A methodological assessment (EHF-EHC 2025) - "[6] who reported changes in the relative effect of sumatriptan over time. ITCs of acute migraine trials, sometimes conducted decades apart, acknowledge heterogeneity but did not attempt to statistically adjust for it. More sophisticated analytical approaches are needed to obtain unbiased and reliable estimates of indirect comparative effectiveness."

Clinical • Heterogeneity • CNS Disorders • Migraine • Pain

Dynamic boronate ester crosslinked hyaluronic acid hydrogel patch enabling fast dissolution and rapid oral mucosal delivery of amorphous sumatriptan. (PubMed, Carbohydr Polym) - "Cytocompatibility and in vivo oral ulcer healing evaluations demonstrated favorable biocompatibility and therapeutic efficacy. This work presents a promising platform for rapid, effective, and patient-friendly oral mucosal drug delivery."

Journal

Cardiac arrest following sumatriptan intake: a case report of a complex diagnostic process. (PubMed, Pol Arch Intern Med) - No abstract available

Journal • Cardiovascular